奥沙利铂联合替吉奥与改良FOLFOX6一线治疗晚期结直肠癌的疗效比较

Comparison of S-1 Combined with Oxaliplatine and Modified FOLFOX6 in the First-line Therapy of Advanced Colorectal Cancer

目的比较奥沙利铂联合国产替吉奥方案(SOX)与改良FOLFOX6方案(m FOLFOX6)一线治疗晚期结直肠癌的近期疗效、远期疗效和安全性。方法将43例晚期结直肠癌完全随机分为A、B组,A组采用SOX联合化疗方案,B组采用m FOLFOX6方案。2组患者均接受至少2个周期化疗,每2个周期评判1次近期疗效。结果 SOX组与m FOLFOX6组有效率(RR)分别为54.5%和52.4%,疾病控制率(DCR)分别为86.4%和90.5%,两组比较无显著性差异(P>0.05)。SOX组与m FOLFOX6组中位肿瘤进展时间(TTP)分别为8.6个月和8.2个月,差异无统计学意义(P>0.05)。2组不良反应均比较轻,SOX组恶心、呕吐发生率低于m FOLFOX6组,差异有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥与改良FOLFOX6一线治疗晚期结直肠癌疗效相似,但耐受性稍好。

Objective To compare the short-term efficacy,long-term efficacy and safety of S-1 combined with oxaliplatine( SOX) and modified FOLFOX6( m FOLFOX6) in the first-line therapy of advanced colorectal cancer. Methods 43 patients with advanced colorectal cancer were randomly divided into group A and group B. Group A adopted SOX combined with chemotherapy,while group B was treated with m FOLFOX6. Patients in both groups received at least 2 cycles of chemotherapy,and shortterm efficacy were evaluated once every 2 cycles. Results In SOX and m FOLFOX6 group,the response rates( RR) were 54. 5%and 52. 4%,the disease control rates( DCR) were 86. 4% and 90. 5%,There were no significant differences between the 2 groups( P > 0. 05). In SOX and m FOLFOX6 group,the median time to progression( TTP) were 8. 6 months and 8. 2 months,There were no significant differences( P > 0. 05). Adverse reactions were relatively light,incidence of nausea and vomiting in the SOX group were significantly lower than that of the m FOLFOX6 group,There were significant differences( P < 0. 05). Conclusion SOX for advanced colorectal cancer has similar efficacy with m FOLFOX6,but SOX has better tolerability.